Evidence map›Paper›PMID 41674995›Full record

ArticleJAC-antimicrobial resistance2026

Within-host evolution of drug tolerance in

Valerie F A March, Kakha Mchedlishvili, Galo A Goig, Nino Maghradze, Teona Avaliani, Rusudan Aspindzelashvili, Zaza Avaliani, Maia Kipiani, Nestani Tukvadze, Levan Jugheli and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Valerie F A MarchDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Kakha MchedlishviliDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Galo A GoigDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Nino MaghradzeDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Teona AvalianiNational Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia.
Rusudan AspindzelashviliNational Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia.
Zaza AvalianiNational Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia.
Maia KipianiNational Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia.
Nestani TukvadzeDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.ORCID https://orcid.org/0000-0002-0276-1204
Levan JugheliDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Selim BouaouinaDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Anna DoetschDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Sevda KalkanDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Miriam ReinhardDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Sebastien GagneuxDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Sonia BorrellDepartment of Research, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.

Funding

Emory-Georgia TB Research Training ProgramD43TW007124 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Nestani Tukvadze · 2004 to 2026
$4.6M
FIC NIH HHS D43 TW007124
6 · The paper itself

Abstract

Background and objectives: Methods: We collected serial Mtb isolates from patients with (i) drug-susceptible TB who remained culture positive for up to 6 years (i.e. recalcitrant TB), and (ii) multidrug-resistant TB (MDR-TB) where resistance amplified during treatment. We measured tolerance to rifampicin in drug-susceptible TB strains and tolerance to moxifloxacin in MDR-TB strains using a real-time time-kill assay. Results and discussion: Rifampicin tolerance evolved within-host, increasing up to and ∼1.5-fold, however, there was no apparent contribution of rifampicin tolerance to delayed culture conversion. Tolerance to moxifloxacin in MDR-TB patients appeared negatively associated with resistance amplification and consistently decreased over time in patients. Conclusion: Our findings confirm that antibiotic tolerance evolves in Mtb within patients over time during treatment. However, there was no evidence that this tolerance influences treatment responses, calling for further investigation of contributors to adverse treatment responses and their mitigation.

Identifiers

PMID41674995
PMCPMC12887598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.